Challenges in launching multinational oncology clinical trials in India.
In the recent past, there has been an impressive growth in the number of clinical trials launched worldwide, including India. Participation in well-designed oncology clinical trials is of advantage to Indian healthcare system in general, and cancer patients in particular. However, the number of clinical trials being run in India is not commensurate with the cancer burden prevailing in the country. In this article, the authors investigate the reasons for this discrepancy, highlight critical bottlenecks, and propose ways to ameliorate the situation.
Breast International Group, Department of Medical Oncology, Jules Bordet Institute, Université libre de Bruxelles, Brussels, Belgium.
Kamal S
KS
Saini
Department of Endocrine and Breast Surgery, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.
Gaurav
G
Agarwal
Clinical Research, AstraZeneca Pharma India Ltd., Bangalore, Karnataka, India.
Ramesh
R
Jagannathan
Breast Oncology Center, Dana-Farber Cancer Institute, Boston, USA.
Otto
O
Metzger-Filho
Department of Anatomie Pathologique, Cliniques Saint Luc, Université catholique de Louvain, Brussels, Belgium.
Monika L
ML
Saini
Indian Cooperative Oncology Network, Mumbai, Maharashtra, India.
Khurshid
K
Mistry
INDOX Cancer Research Network, University of Oxford, Oxford, UK.
Raghib
R
Ali
Department of Medical Oncology, Tata Memorial Centre, Mumbai, Maharashtra, India.
Sudeep
S
Gupta
Cancer; India; South Asia; challenges; clinical trials; delays; obstacles; oncology; regulatory; research